{"id":"NCT01134198","sponsor":"New York State Psychiatric Institute","briefTitle":"Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients","officialTitle":"Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-05","primaryCompletion":"2016-09","completion":"2018-02-14","firstPosted":"2010-05-31","resultsPosted":"2018-08-24","lastUpdate":"2018-12-20"},"enrollment":58,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cocaine Dependence"],"interventions":[{"type":"DRUG","name":"Mifepristone","otherNames":["RU486"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Mifepristone","type":"ACTIVE_COMPARATOR"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This research will evaluate the impact of blocking central and peripheral glucocorticoid receptors on stress sensitivity and the risk of relapse to cocaine use in treatment-seeking cocaine-dependent individuals. Mifepristone (RU-486) will be the glucocorticoid antagonist used.","primaryOutcome":{"measure":"Number of Participants With Relapse by Days 10 and 28","timeFrame":"assessed during 8 weeks of trial, but reported for days 10 and 28 of trial","effectByArm":[{"arm":"Mifepristone","deltaMin":3,"sd":null},{"arm":"Placebo","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["nausea","fatigue","constipation","weakness","insomnia/hypersomnia"]}}